News

NVA237 is a collaborative product of Sosei and Vectura that is being developed and commercialized by Novartis, both as a monotherapy and in combination with its once-daily bronchodilator

The companies will collaborate on the development of the product and co-commercialize Hematide in the US, while Takeda will hold an exclusive license to develop and commercialize outside

Under the terms of the proposal, Pliva's shareholders would receive approximately HRK705 ($122) for each share they hold in the company. The offer represents a premium of 24%

Under the terms of the agreement, Aurigene will contribute its expertise in discovery and in-vivo optimisation of lead compounds, whilst drug development expertise will be provided by Debiopharm.

Cephalon said that it will conduct a complete analysis of the data to assist in its evaluation of future clinical development plans for Gabitril in other therapeutic areas.

Neovascular age-related macular degeneration (AMD) is a chronic, progressive disease that may require ongoing management. The 54-week trial will enroll up to 1000 patients at 100 sites across

The pivotal trial will compare thrombin topical (human) to bovine thrombin in achieving intra-operative hemostasis (contol of bleeding) during cardiovascular, neurologic (spine) and general surgery procedures. A total

The new agreement supersedes a previous collaboration agreement entered into by Targeted Genetics, with the International Aids Vaccine Initiative (IAVI) and Columbus Children's Research Institute (CCRI) in 2000,

IR103 is a co-formulation of Remune and a novel synthetic toll-like receptor (TLR-9) agonist adjuvant, Amplivax. The company presented the results at the International Symposium on HIV &